Defender Pharmaceuticals

About Defender Pharmaceuticals

Defender Pharmaceuticals, Inc., founded in 2014, is a privately held life sciences company based in St. Louis, Missouri. The company was established by Founder and Executive Chairman, Francis E. O'Donnell, Jr., MD. Defender Pharmaceuticals operates in the drug discovery and pharmaceuticals sector, focusing on developing and commercializing therapies for civilian and military populations, including first responders and astronauts. The company's business model centers on the development and out-licensing of its drug candidates, funded by venture capital, with $70 million raised to date.

The company's primary product candidate is DPI-386, an intranasal gel formulation of scopolamine for the prevention of nausea and vomiting induced by motion. This delivery system is designed for rapid absorption and fast-acting relief. While the New Drug Application for DPI-386 received a Complete Response Letter from the FDA in January 2024, the company is working to address the issues raised. Defender is also exploring scopolamine for other therapeutic areas, such as major depressive disorder and as a countermeasure to chemical warfare agents. Their pipeline also includes a significant collaboration with the U.S. Army, initiated in July 2023, to develop and commercialize eight investigational vaccines against various tropical diseases, including tularemia and chikungunya. This agreement involves the transfer of the Army's existing Investigational New Drug applications to Defender for further development and commercialization.

Defender Pharmaceuticals actively partners with U.S. government agencies, which are its primary client base. Key collaborations include a multi-year research effort with NASA to study DPI-386 for mitigating motion sickness in astronauts and an exclusive license agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) for its tropical disease vaccine pipeline. These partnerships underscore the company's focus on addressing the specific medical needs of military and aerospace personnel, positioning itself as a key supplier of specialized medical countermeasures. The company's strategy relies on leveraging its relationships with government entities to advance its products through the regulatory and development process.